CBUS Stock Summary and Trading Ideas (Cibus - Class A | NASDAQ:CBUS)

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Cibus - Class A trades on the NASDAQ stock market under the symbol CBUS.

As of April 1, 2026, CBUS stock price declined to $1.94 with 450,970 million shares trading.

CBUS has a beta of 3.00, meaning it tends to be more sensitive to market movements. CBUS has a correlation of 0.18 to the broad based SPY ETF.

CBUS has a market cap of $147.78 million. This is considered a Micro Cap stock.

Last quarter Cibus - Class A reported $1 million in Revenue and -$.42 earnings per share. This fell short of revenue expectation by $-517,202 and missed earnings estimates by -$.16.

The top ETF exchange traded funds that CBUS belongs to (by Net Assets): VTI, VXF, IWC, KROP, DFMC.

CBUS has underperformed the market in the last year with a price return of +3.7% while the SPY ETF gained +18.5%. However, in the short term, CBUS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +11.5% vs -3.6% return in SPY. But in the last 2 weeks, CBUS shares have been beat by the market, returning -47.3% compared to an SPY return of -2.0%.

CBUS support price is $1.82 and resistance is $2.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CBUS shares will trade within this expected range on the day.